Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Neurocrine Biosciences Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while Neurocrine Biosciences Inc trades at $135.83 (market cap $14.37B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| GEHC | NBIX | |
|---|---|---|
Market Cap | $31.07B | $14.37B |
Volume | 3,443,020 | 1,081,559 |
Sector | Health | Health |
52-Week High | $88.16 | $185.50 |
52-Week Low | $59.48 | $123.10 |
Enterprise Value | $39.53B | $14.38B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 24 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Neurocrine Biosciences (NBIX) trades at $135.13, down 4.41% over 24 hours amid a broader bearish technical signal, though key moving averages and oscillators show mixed signals. Fundamentally, the company demonstrates robust health with a 97.91% gross profit margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 against a $1.85 expectation. Recent news highlights pipeline advancements, including presentations on Prader-Willi syndrome research and executive appointments, supporting long-term growth narratives beyond its flagship product INGREZZA.
The investment outlook for NBIX is positive, driven by strong analyst consensus with a $204.18 price target and 86.49% buy ratings, reflecting confidence in revenue growth and pipeline diversification. Key risks include execution challenges in commercializing new products and potential pricing pressures on INGREZZA post-2029. Investors should weigh the company's high profitability and cash flow generation against these sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
